Merck Wins Two Suits Against Mylan

WHITEHOUSE STATION, N.J. -- Drugmaker Merck & Co. ( MRK) has won two patent infringement lawsuits against a generic drugmaker seeking to make copycat versions of its lucrative cholesterol pills, Zetia and Vytorin.

Merck says U.S. District Judge José Linares in Newark, N.J., ruled Friday against Mylan Pharmaceuticals Inc. ( MYL)

> > Bull or Bear? Vote in Our Poll

Both lawsuits concern the patent for ezetimibe, Zetia's active ingredient and a part of Vytorin, which also includes generic Zocor. That's an older Merck cholesterol pill that works differently.

The judge ruled the patent, which runs until April 2017, is valid, so Mylan cannot make generic versions of the drugs until then.

In the first quarter, Zetia had sales of $614 million and Vytorin dipped to $444 million. Together, they had 2011 sales of $4.3 billion.
Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts